KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Equity Ratio (2016 - 2026)

Eli Lilly filings provide 18 years of Equity Ratio readings, the most recent being 0.27 for Q1 2026.

  • On a quarterly basis, Equity Ratio rose 1196.34% to 0.27 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.27, a 1196.34% increase, with the full-year FY2025 number at 0.24, up 7448.86% from a year prior.
  • Equity Ratio hit 0.27 in Q1 2026 for Eli Lilly, up from 0.24 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.27 in Q1 2026 to a low of 0.09 in Q2 2022.
  • Median Equity Ratio over the past 5 years was 0.02 (2025), compared with a mean of 0.01.
  • Biggest five-year swings in Equity Ratio: plummeted 3106.51% in 2024 and later soared 7448.86% in 2025.
  • Eli Lilly's Equity Ratio stood at 0.0 in 2022, then crashed by 2660.06% to 0.05 in 2023, then surged by 106.64% to 0.0 in 2024, then skyrocketed by 7448.86% to 0.24 in 2025, then increased by 13.44% to 0.27 in 2026.
  • The last three reported values for Equity Ratio were 0.27 (Q1 2026), 0.24 (Q4 2025), and 0.21 (Q3 2025) per Business Quant data.